Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Dec 20;99:104922. doi: 10.1016/j.ebiom.2023.104922

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Fig. 1 — naNO-DENGUE trial profile. Participants were enrolled according to a dose-escalation protocol and randomly assigned within each dose group to receive two doses of PepGNP-Dengue (gold nanoparticles and dengue peptides) or vehicle-GNP (gold nanoparticles only). Two participants did not receive the second vaccination: one because of consent withdrawal (PepGNP-Dengue low dose group) and one because of grade 3 erythema at the injection site (vehicle-GNP high dose group). All participants completed 180 days of follow-up. GNP = gold nanoparticles.